These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 30785697)

  • 1. Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?
    Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi PF
    Int Braz J Urol; 2019; 45(2):315-324. PubMed ID: 30785697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer.
    Mbeutcha A; Shariat SF; Rieken M; Rink M; Xylinas E; Seitz C; Lucca I; Mathieu R; Rouprêt M; Briganti A; Karakiewicz PI; Klatte T
    Urol Oncol; 2016 Nov; 34(11):483.e17-483.e24. PubMed ID: 27646875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of preoperative neutrophil to lymphocyte ratio in prediction of recurrence, progression, and BCG failure in non-muscle invasive bladder cancer: a retrospective study.
    Ziani I; Ibrahimi A; Zaoui Y; El Sayegh H; Abouqal R; Nouini Y; Bouziane A
    Pan Afr Med J; 2023; 44():145. PubMed ID: 37396698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer.
    Mano R; Baniel J; Shoshany O; Margel D; Bar-On T; Nativ O; Rubinstein J; Halachmi S
    Urol Oncol; 2015 Feb; 33(2):67.e1-7. PubMed ID: 25060672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer.
    Cantiello F; Russo GI; Vartolomei MD; Farhan ARA; Terracciano D; Musi G; Lucarelli G; Di Stasi SM; Hurle R; Serretta V; Busetto GM; Scafuro C; Perdonà S; Borghesi M; Schiavina R; Cioffi A; De Berardinis E; Almeida GL; Bove P; Lima E; Ucciero G; Matei DV; Crisan N; Verze P; Battaglia M; Guazzoni G; Autorino R; Morgia G; Damiano R; de Cobelli O; Mirone V; Shariat SF; Ferro M
    Eur Urol Oncol; 2018 Oct; 1(5):403-410. PubMed ID: 31158079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.
    Singla N; Haddad AQ; Passoni NM; Meissner M; Lotan Y
    World J Urol; 2017 Jan; 35(1):105-111. PubMed ID: 27194044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer.
    Thiel T; Ryk C; Renström-Koskela L; Steineck G; Schumacher MC; Wiklund NP; de Verdier PJ
    World J Urol; 2019 Jan; 37(1):155-163. PubMed ID: 29905887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K; Chihara Y; Kondo H; Hirao Y
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation.
    Nieder AM; Simon MA; Kim SS; Manoharan M; Soloway MS
    Urology; 2006 Apr; 67(4):737-41. PubMed ID: 16618564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of pretreatment inflammation-based prognostic scores (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio) for invasive bladder carcinoma.
    Lee SM; Russell A; Hellawell G
    Korean J Urol; 2015 Nov; 56(11):749-55. PubMed ID: 26568792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor.
    Kang M; Jeong CW; Kwak C; Kim HH; Ku JH
    Oncotarget; 2017 Feb; 8(8):12891-12901. PubMed ID: 28039452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oncological outcome of radical cystectomy for BCG failure compared to primary invasive disease].
    Masson-Lecomte A; Vordos D; Yiou R; Allory Y; Abbou C; de la Taille A; Salomon L
    Prog Urol; 2013 Jun; 23(7):456-63. PubMed ID: 23721705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer.
    Vartolomei MD; Ferro M; Cantiello F; Lucarelli G; Di Stasi S; Hurle R; Guazzoni G; Busetto GM; De Berardinis E; Damiano R; Perdona S; Verze P; La Rocca R; Borghesi M; Schiavina R; Brunocilla E; Almeida GL; Bove P; Lima E; Grimaldi G; Autorino R; Crisan N; Abu Farhan AR; Battaglia M; Serretta V; Russo GI; Morgia G; Terracciano D; Musi G; de Cobelli O; Mirone V; Shariat SF
    Clin Genitourin Cancer; 2018 Dec; 16(6):445-452. PubMed ID: 30077463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy].
    Huguet J; Gaya JM; Sabaté S; Palou J; Villavicencio H
    Actas Urol Esp; 2010 Jan; 34(1):63-70. PubMed ID: 20223134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer.
    Ferro M; Vartolomei MD; Russo GI; Cantiello F; Farhan ARA; Terracciano D; Cimmino A; Di Stasi S; Musi G; Hurle R; Serretta V; Busetto GM; De Berardinis E; Cioffi A; Perdonà S; Borghesi M; Schiavina R; Cozzi G; Almeida GL; Bove P; Lima E; Grimaldi G; Matei DV; Crisan N; Muto M; Verze P; Battaglia M; Guazzoni G; Autorino R; Morgia G; Damiano R; de Cobelli O; Shariat S; Mirone V; Lucarelli G
    World J Urol; 2019 Mar; 37(3):507-514. PubMed ID: 29992381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy.
    Palou-Redorta J; Solsona E; Angulo J; Fernández JM; Madero R; Unda M; Martínez-Piñeiro JA; Portillo J; Chantada V; Moyano JL
    Actas Urol Esp; 2016; 40(6):370-7. PubMed ID: 26922518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.